Given the discussions above on Biogen's decision and neurofilament biomarkers, this comment jumped out at me in this article :
https://endpts.com/biogen-and-ionis-abandon-als-drug-after-disappointing-early-stage-trial/
That's pretty big news for PAA and MPL.
Frontotemporal degeneration stands out as a very adjacent indication to MND/ALS , and if MPL is proven efficacious against MND ( including +ve results in NfL's ) , odds on it would also prove efficacious against FTD - and neurofilament markers would qualify as a validated endpoint in clinical studies.
Ann: PharmAust receives Orphan Drug Designation for monepantel, page-43
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.0¢ | $83.08K | 474.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 376717 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 144077 | 1 |
View Market Depth
| Last trade - 15.41pm 10/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |